373 related articles for article (PubMed ID: 20053474)
1. Retail price regulation and innovation: reference pricing in the pharmaceutical industry.
Bardey D; Bommier A; Jullien B
J Health Econ; 2010 Mar; 29(2):303-16. PubMed ID: 20053474
[TBL] [Abstract][Full Text] [Related]
2. Toward Value-Based Pricing to Boost Cancer Research and Innovation.
Ocana A; Amir E; Tannock IF
Cancer Res; 2016 Jun; 76(11):3127-9. PubMed ID: 27197164
[TBL] [Abstract][Full Text] [Related]
3. Examining the link between price regulation and pharmaceutical R&D investment.
Vernon JA
Health Econ; 2005 Jan; 14(1):1-16. PubMed ID: 15386673
[TBL] [Abstract][Full Text] [Related]
4. [Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].
Stargardt T; Schreyögg J; Busse R
Gesundheitswesen; 2005 Jul; 67(7):468-77. PubMed ID: 16103970
[TBL] [Abstract][Full Text] [Related]
5. Comparative approaches to pharmaceutical price regulation in the European Union.
Mrazek MF
Croat Med J; 2002 Aug; 43(4):453-61. PubMed ID: 12187524
[TBL] [Abstract][Full Text] [Related]
6. Pharmaceutical policy in Italy: towards a structural change?
Ghislandi S; Krulichova I; Garattini L
Health Policy; 2005 Apr; 72(1):53-63. PubMed ID: 15760698
[TBL] [Abstract][Full Text] [Related]
7. The drug bargaining game: pharmaceutical regulation in Australia.
Wright DJ
J Health Econ; 2004 Jul; 23(4):785-813. PubMed ID: 15587698
[TBL] [Abstract][Full Text] [Related]
8. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.
Sollano JA; Kirsch JM; Bala MV; Chambers MG; Harpole LH
Clin Pharmacol Ther; 2008 Aug; 84(2):263-6. PubMed ID: 18547999
[TBL] [Abstract][Full Text] [Related]
9. Points to consider about prescription drug prices: an overview of federal policy and pricing studies.
Kucukarslan S; Hakim Z; Sullivan D; Taylor S; Grauer D; Haugtvedt C; Zgarrick D
Clin Ther; 1993; 15(4):726-38. PubMed ID: 8221823
[TBL] [Abstract][Full Text] [Related]
10. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
Pavenik N
Rand J Econ; 2002; 33(3):469-87. PubMed ID: 12585303
[TBL] [Abstract][Full Text] [Related]
11. Reference pricing of pharmaceuticals.
Brekke KR; Königbauer I; Straume OR
J Health Econ; 2007 May; 26(3):613-42. PubMed ID: 17188769
[TBL] [Abstract][Full Text] [Related]
12. Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach.
Augurzky B; Göhlmann S; Gress S; Wasem J
Health Econ; 2009 Apr; 18(4):421-36. PubMed ID: 18677725
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacoeconomics--survey and status].
Pedersen KM
Ugeskr Laeger; 2003 Apr; 165(16):1670-4. PubMed ID: 12756827
[TBL] [Abstract][Full Text] [Related]
14. Price-cap Regulation, Uncertainty and the Price Evolution of New Pharmaceuticals.
Shajarizadeh A; Hollis A
Health Econ; 2015 Aug; 24(8):966-77. PubMed ID: 24990225
[TBL] [Abstract][Full Text] [Related]
15. Price regulation and generic competition in the pharmaceutical market.
Dalen DM; Strøm S; Haabeth T
Eur J Health Econ; 2006 Sep; 7(3):208-14. PubMed ID: 16841230
[TBL] [Abstract][Full Text] [Related]
16. [International reference prices and cost minimization analysis for the regulation of medicine prices in Colombia].
Vacca C; Acosta A; Rodriguez I
Value Health; 2011; 14(5 Suppl 1):S16-9. PubMed ID: 21839891
[TBL] [Abstract][Full Text] [Related]
17. Launch prices for new pharmaceuticals in the heavily regulated and subsidized Spanish market, 1995-2007.
Puig-Junoy J; López-Valcárcel BG
Health Policy; 2014 Jun; 116(2-3):170-81. PubMed ID: 24641938
[TBL] [Abstract][Full Text] [Related]
18. The price of innovation: new estimates of drug development costs.
DiMasi JA; Hansen RW; Grabowski HG
J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142
[TBL] [Abstract][Full Text] [Related]
19. Prices of pharmaceuticals in poor countries are much lower than in wealthy countries.
Schweitzer SO; Comanor WS
Health Aff (Millwood); 2011 Aug; 30(8):1553-61. PubMed ID: 21821573
[TBL] [Abstract][Full Text] [Related]
20. A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators.
Hu S; Zhang Y; He J; Du L; Xu M; Xie C; Peng Y; Wang L
Appl Health Econ Health Policy; 2015 Aug; 13 Suppl 1(Suppl 1):S13-20. PubMed ID: 26091710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
